As approved by the FDA, to end the HIV epidemic, the FDA has come up with a second drug that shall prevent HIV infection as part of ongoing efforts. A drug called Descovy was approved by the U.S. Food and Drug Administration today in over-weighted adolescents (35Kg) and at high-risk adults for HIV-1pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex.
Descovy is not directed to them who have HIV-1 infection from receptive vaginal sex due to non-evaluation of its effectiveness in its population. As the drug PrEP is more effective when taken as directed on its level, which shall reduce the infection to a lot of extents. As it got the approval, many of the infected patients will get benefitted from it due to its further prevention measures or effects and will increase its efforts by FDA.
This drug will further help in the development of HIV prevention, treatments, and infections. According to the Act of prevention and centers for disease control, 38,739 people have be diagnosed in HIV in the year 2017 at the U.S. In order to stop this epidemic, President Donald Trump had taken an initiative called ‘A plan for America’ to end this HIV epidemic on the year 2019 of date 5th February of his state of the Union Address.
The main agenda of this plan is to provide advanced technology diagnosis to the patients and to eliminate the disease in every possible way that can reduce HIV infections to spread further.
This initiative will provide the highly suffered communities with expertise level resources and technological drugs to at least end their infection up to 75% in the next five years and 90% by next ten years if not less than that. Around 250,000 infections will be averted by these years if all of the measures are succeeded in the following years.